NSRX

6-K - Nasus Pharma Ltd (0002029039) (Filer)

TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 pharmacokinetic (PK) trial of NS003, its proprietary intranasal powder formulation of ondansetron being developed for chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). In a recent pre-clinical study comparing NS003 to the intravenous ("IV") formulation of ondansetron in animals, results showed that NS003 had a PK profile comparable to the

3 - Nasus Pharma Ltd (0002029039) (Issuer)

4 - Nasus Pharma Ltd (0002029039) (Issuer)

424B5 - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional Pivotal Study is planned for the fourth quarter of 2026; topline data readout anticipated first quarter 2027 TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational

EFFECT - Nasus Pharma Ltd (0002029039) (Filer)

TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel. The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal Rubin, Chief Financial Officer, will be available for one-on-one

6-K - Nasus Pharma Ltd (0002029039) (Filer)

F-3 - Nasus Pharma Ltd (0002029039) (Filer)

EFFECT - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition. Oren Elmaliach, the Company’s Director of Finance, has been appointed Interim Chief Financial Officer. "I have known Eyal for over a decade and have always admired his con

6-K - Nasus Pharma Ltd (0002029039) (Filer)

Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced its financial results for the six months ending June 30, 2026 and provided a corporate update. "Nasus has made enormous progress in its clinical programs in the first six months of 2026, and we believe it is well positioned to advance to NS002 and NS003 toward key milestones in the second hal

SCHEDULE 13G/A - Nasus Pharma Ltd (0002029039) (Subject)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

4 - Nasus Pharma Ltd (0002029039) (Issuer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O'Grady as its Chief Executive Officer. Mr. O'Grady will lead the Company's next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the Company's pipeline and business development initiatives, and maximizing the value of its proprietary Nasax® intranasal technology platform. Mr. O'Grady succeeds Dan Teleman, with the leadership transition effective Jul

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management will present live at the Zacks Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, to be held virtually on June 24-25, 2026. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. Nasus invites individual and institutional investors, as well as advisors and